J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Expression of p16INK4a as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy
Julie A. E. Nelson,Janakiraman Krishnamurthy,Prema Menezes,Yan Liu,Michael G. Hudgens,Norman E. Sharpless,Joseph J. Eron +6 more
TL;DR: The data show that p16INK4a is a reliable biomarker of T‐cell aging in HIV+ patients with suppressed viral loads and suggest that poor CD4 cell recovery on cART may be associated with increased T‐ cell expression of p16ink4a, a marker of cellular senescence.
Journal ArticleDOI
The detection and management of early HIV infection: A clinical and public health emergency
M. Kumi Smith,Sarah E. Rutstein,Kimberly A. Powers,Sarah Fidler,William C. Miller,Joseph J. Eron,Myron S. Cohen +6 more
TL;DR: An increasing body of evidence supports the use of immediate antiretroviral therapy to treat EHI to maintain CD4 count and functionality, limit the size of the HIV reservoir, and reduce the risk of onward viral transmission.
Journal ArticleDOI
Clones of infected cells arise early in HIV-infected individuals
John M. Coffin,David Wells,Jennifer M. Zerbato,Joann D. Kuruc,Shuang Guo,Brian T. Luke,Joseph J. Eron,Michael J. Bale,Jonathan Spindler,Francesco R. Simonetti,Shawn Hill,Mary F. Kearney,Frank Maldarelli,Xiaolin Wu,John W. Mellors,Stephen H. Hughes +15 more
TL;DR: Some infected clones could be detected approximately 4 weeks after HIV infection and some of these clones persisted for years, helping to explain how the reservoir is established early and persists for years.
Journal ArticleDOI
The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11
Catherine R. Lesko,Catherine R. Lesko,Stephen R. Cole,H. Irene Hall,Daniel Westreich,William C. Miller,Joseph J. Eron,Jianmin Li,Michael J. Mugavero +8 more
TL;DR: Immediate ART initiation substantially lowers mortality among persons in the CNICS and this benefit is expected to be similar among persons recently diagnosed with HIV in the USA.
Journal ArticleDOI
Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1
TL;DR: Potential unmet needs with respect to combination antiretroviral therapy (cART) remain, including cardiovascular and metabolic complications, and neurocognitive impairment and malignancy are important sources of ongoing morbidity despite cART.